A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Part of paid clinical trials in Sarasota, Florida.
- Sponsor
- Blueprint Medicines Corporation
- Study ID
- NCT07629960
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Advanced Solid Tumor
- Colorectal Neoplasms
- Non-Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BLU-924 — DRUGTablet
Study Details
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
Key Dates
- First listed
- Jun 5, 2026
- Start date
- Jun 4, 2026
- Status verified
- Aug 2026
- Primary completion
- Sep 30, 2029
- Completion
- Jul 31, 2031
Study Design
- Enrollment
- 265 participants (estimated)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Monotherapy Part: BLU-924 Dose Escalation, Dose Enrichment, and Dose ExpansionParticipants will receive BLU-924 oral tablet, once daily as monotherapy during Dose Escalation followed by Dose Enrichment. During Dose Enrichment, participants with PDAC, NSCLC or CRC will receive BLU-924 at selected dose levels below the current escalation dose or, if Dose Escalation is complete, below the MTD. During Dose Expansion, participants will receive RDFE of BLU-924 oral tablet, once daily as monotherapy determined during escalation monotherapy part. Dose Expansion may be initiated to further assess the safety, antitumor activity, PK, and pharmacodynamics of BLU-924 at RDFE in indication-specific cohorts (PDAC, NSCLC, or CRC) harboring a KRAS mutation.
Primary Outcome Measure
Dose Escalation and Enrichment: Percentage of Participants with Dose-limiting Toxicity (DLTs) [ Time Frame: Up to 5 years ]
Central Contacts
- Blueprint Medicines1-888-258-7768
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specialists & Research Institute - Sarasota | Sarasota | Florida | 34242 | - |
| Moffitt Cancer Center | Tampa | Florida | 33612 | - |
| Next Oncology Virginia Cancer Specialist | Fairfax | Virginia | 22031 | - |
Find similar trials in Sarasota, FL
Nationwide
By condition
By specialty
Related Studies
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPHASE3 · Recruiting · University of Texas Southwestern Medical Center · Savannah, Georgia
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal CancerPHASE3 · Recruiting · Surgimab · Duarte, California
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia